Assess whether RWE can replace or only supplement an RCT from phase-3

Situation

Phase-3 protocol with endpoint-sensitivity issues arrived with a pediatric ethicist objecting to the proposed design for pediatric-plan strategist. That is a Pharma & Life Sciences FDA Response and Labeling decision on RWE can replace or in an RWE group proposing a post-marketing study instead of a new RCT.

Decision

Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose RWE can replace / Only supplement an RCT using phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• Phase-3 protocol with endpoint-sensitivity issues reads as RWE can replace once a pediatric ethicist objecting to the proposed design is lined up to the same Pharma & Life Sciences population.
• Phase-3 protocol with endpoint-sensitivity issues is closer to Only supplement an RCT after a pediatric ethicist objecting to the proposed design; RWE can replace would over-claim this FDA Response and Labeling extract.
• A dual reading is still live in phase-3 protocol with endpoint-sensitivity issues for pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT.
• Phase-3 protocol with endpoint-sensitivity issues is missing the fact pediatric-plan strategist needs after a pediatric ethicist objecting to the proposed design; stop this Pharma & Life Sciences close.

Analysis required

• Check whether phase-3 protocol with endpoint-sensitivity issues supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design.
• For this Pharma & Life Sciences FDA Response and Labeling file, read phase-3 protocol with endpoint-sensitivity issues against a pediatric ethicist objecting to the proposed design and write the one fact that would move RWE can replace or for pediatric-plan strategist.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / FDA Response and Labeling packet (phase-3 protocol with endpoint-sensitivity issues after a pediatric ethicist objecting to the proposed design). The follow-on FDA Response and Labeling action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.